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Background: Complement mediated autoimmunity against aquaporin-4 results in astrocytic damage in neu-
romyelitis optica (NMO). There is evidence for increased CSF glial ﬁbrillary acidic protein (GFAP) and S100B
levels in acute NMO. Here we tested whether the CSF ﬁnding also holds true for the diagnostic value of serum
GFAP and S100B levels in NMO.
Methods: A multicentre study included 322 patients from London (n=160), Nijmegen (n=95), Pecs (n=44),
and Lyon (n=24). Patients were classiﬁed into the following diagnostic categories: neurological control patients
(n=45),MS optic neuritis (MSON, n=38), isolated optic neuritis (ION, n=11), relapsing isolated optic neuritis
(RION, n=48), chronic relapsing isolated optic neuropathy (CRION, n=18), unclassiﬁed optic neuritis (UCON,
n=39), NMO (n=77) and relapsing remittingmultiple sclerosis (RRMS, n=47). Serum GFAP and S100B levels
were quantiﬁed using ELISA.
Results:Median serum GFAP but not S100B levels were signiﬁcantly higher (pb0.0001, general linear model) in
patients with NMO (4.83 pg/mL) if compared to MSON (1.5 pg/mL, p=0.0001), UCON (1.92 pg/mL, pb0.01),
ION (0.0 ng/mL, pb0.05), RION (1.3 pg/mL, pb0.0001) and CRION (2.2 pg/mL, p=0.01). Serum GFAP levels
in the control cohort (3.6 pg/mL) were not signiﬁcantly different to NMO. There was no relationship between
serum GFAP levels and any other clinical or demographic parameter. Serum S100B concentrations correlated
with the number of relapses in MSON (R=0.83, p=0.005).
Conclusion: In contrast to the CSF, neither serum GFAP nor S100B levels were of major diagnostic value for
the laboratory supported differential diagnosis between optic neuritis in the context of NMO and other optic
neuropathies.© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
The auto-antibody (NMO-IgG) described by Lennon et al. [1] binds
to the plasma membrane protein AQP4 expressed at the astrocytic
endfeet that abut capillaries and pia [2]. Autoimmunity against
aquaporin-4 (AQP4) [1,3,4] damages the astrocytes, particularly in
the AQP4 rich areas of the central nervous system (CNS) such as the
optic nerve and spinal cord [5]. The precise mechanism by which
the NMO-IgG acts is not known, but complement activation leadingent of Neurology, De Boelelaan
04445292.
evier OA license.to astrocytic necrosis has been shown by a number of groups [6–8].
In addition, there is experimental evidence for glutamate mediated
excitotoxicity [8]. Following astrocytic destruction, cellular proteins
such as glial ﬁbrillary acidic protein (GFAP) are released leading to
signiﬁcantly elevated CSF GFAP levels during an acute relapse in
NMO [9–12]. The speciﬁcity of GFAP as a biomarker for astrocytic
damage is high. Another slightly less speciﬁc glial biomarker, S100B
was also signiﬁcantly elevated in the CSF during an acute relapse of
NMO [11,12]. Compared to GFAP, S100B is less speciﬁc for astrocytic
damage because it is also expressed by microglia and oligodendro-
cytes of the CNS. Naturally the question arises whether the substan-
tial increase of GFAP and S100B levels in the CSF would also be
reﬂected in the patient's serum.
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S100B levels for the differential diagnosis of NMO in comparison
with optic neuritis associated with MS and three other syndromically
deﬁned varieties of inﬂammatory optic neuropathy in which there is
evidence of neither MS nor NMO [13].
2. Patients and methods
The study was approved by the local Institutional Review Board
(IRB), informed consent was obtained and samples exchanged using
material transfer agreements.
2.1. Patients
This prospective study included 371 patients recruited between
January 2000 and July 2010 at four European centres: London (United
Kingdom), Lyon (France), Nijmegen (The Netherlands) and Pecs
(Hungary). The study included the cohort of 17 patients from London
which has been the subject of a preliminary report [14].
Inclusion criteria for NMO were as published by Wingerchuk et al.
[15]. Of note, in these criteria seropositivity for anti AQP4 antibodies
was not a pre-requisite and by no means the only test performed.
Clearly, MRI was required [16] to allow for the distinction between
classical NMO [15] and the NMO spectrum disorder [17]. Inclusion cri-
teria for MS were the 2001 McDonald criteria [18]. Inclusion criteria
for isolated optic neuritis (ION), multiple sclerosis optic neuritis
(MSON), relapsing isolated optic neuritis (RION) and chronic relapsing
inﬂammatory optic neuropathy (CRION) were as described [13,19].
Brieﬂy, a diagnosis of CRIONwasmade in patients who always relapsed
directly afterwithdrawing immunosuppressive treatment and inwhom
MRI showed pathology restricted to the optic nerve; a diagnosis of RION
wasmade in patients who had a spontaneous relapse of their optic neu-
ritis and inwhomMRI showed pathology restricted to the optic nerve; a
diagnosis of ION was made in patients who had one single episode of
optic neuritis and in whom MRI showed pathology restricted to the
optic nerve. Patients with optic neuritis not ﬁtting any of the above cat-
egories were classiﬁed as UCON (unclassiﬁed optic neuritis). A typical
patient with UCON would be one presenting with a single episode of
optic neuritis in whom the MRI of the brain was not entirely normal,
but not typical for MS or NMO. Of note, in the present study the AQP4
serostatus was not used for classiﬁcation of patients with ION, RION or
UCON as “NMO spectrum disorders” which represent an umbrella for
NMO related systemic autoimmunity relationships now also embracing
rheumatologic diseases such as systemic lupus erythematosus and
Sjögren syndrome [20,21].
Exclusion criteria were any other severe neurological condition such
as a brain tumour, a cerebrovascular accident, cerebral vasculitis, sub-
arachnoid haemorrhage, traumatic brain injury, meningo-encephalitis
or siderosis.
2.2. Serum samples
Blood samples were collected in vacuum tubes. Samples were
spun at 2000 g for 10 min at room temperature. Aliquots were taken
and stored in 1.5 mL polypropylene tubes at −80 °C until further
analysis. Samples were shipped on dry ice to Amsterdam. All samples
arrived safe, still with sufﬁcient dry ice. All serum analyses were done
at a single laboratory (Amsterdam) with the analysts (M.G. and A.P.)
being blinded to all other demographic and clinical details.
2.3. GFAP ELISA
A previously described GFAP ELISA [22] was modiﬁed because of
change of antibody and protein suppliers as follows: microtitre plates
were coated overnight with 100 μL of the mouse monoclonal SMI26
capture antibody (SMI-26R, Covance) and diluted 1/5000 in 0.05 Mcarbonate buffer, pH 9.5. The plate was washed with barbitone buffer
containing 6 mM EDTA, 0.2% BSA and 0.05% Tween 20 (pH 8.6). The
plate was blocked with 150 μL of barbitone buffer containing 6 mM
EDTA and 2% of BSA. After washing, 50 μL of barbitone buffer, 6 mM
EDTA, and 0.2% BSA were added as sample diluent to each well.
Fifty microlitres of standard or serum sample was then added in du-
plicate to the plate. Because of the large number of batch analysed
samples, pipetting time exceeded the previously published 1 h incu-
bation period [22]. The plate was incubated at 4 °C overnight. After
washing, 100 μL of rabbit polyclonal anti bovine GFAP (Z0334,
DAKO) diluted 1:1000 in barbitone buffer (6 mM EDTA, 0.2% BSA)
was added to each well and the plate was incubated for 1 h at RT.
Following another one hour incubation period and wash cycle the
reporter antibody (HRP swine anti-rabbit, P0217, DAKO) was added.
After a ﬁnal one hour incubation and wash cycle, 100 μL of TMB sub-
strate was added. The plate was incubated for 20 min at RT in the
dark, the reaction was stopped by adding 50 μL 2 M H2SO4 and the
absorbance was read at 450 nm with 540 nm as the reference wave-
length on an ELISA plate reader.
The averaged measurement accuracy of the duplicates calculated
to a coefﬁcient of variation of 3.9.
2.4. S100B ELISA
A previously described serum S100B ELISA [23] was modiﬁed
because of change of antibody and protein suppliers as follows: 96-
well micrometre plates were coated with 100 μL 0.05 M carbonate
buffer containing mouse monoclonal anti S100B (S2532, Sigma).
The plates were washed with 0.67 M barbitone buffer containing
5 mM calcium lactate, 0.2% BSA and 0.05% Tween and then blocked
with 150 μL of 2% BSA and washed again. Diluted serum (1:1) in
0.67 M barbitone buffer containing 5 mM calcium lactate was added
in duplicate. After incubation (as for GFAP at 4 °C, overnight) and
wash polyclonal rabbit anti S100B (HPA015768, Sigma) was added.
Following another one hour incubation period and wash cycle the
reporter antibody (HRP swine anti-rabbit, P0217, DAKO) was added.
After a ﬁnal one hour incubation and wash cycle, the plate was incu-
bated for 20 min at RT in the dark, the reaction was stopped by adding
50 μL 2 M H2SO4 and the absorbance was read at 450 nmwith 540 nm
as the reference wavelength on an ELISA plate reader.
The averaged measurement accuracy of the duplicates calculated
to a coefﬁcient of variation of 4.8.
2.5. AQP4 serology
The serostatus for AQP4 was determined using different assays. For
the French cohort we used a cell-based assay with HEK transfected with
high amount of AQP4-M1 isoform as described [8]. For the Hungarian
cohort we used two cell-based assays, a commercially available one
(EUROIMMUN AG, Lübeck, Germany) and an in-house assay kindly pro-
vided by the group of Bernhard Hemmer [24]. For the Dutch cohort
samples were analysed by a commercial kit (Sanquin, Amsterdam, The
Netherlands) [25]. For the English cohort samples were analysed by
the cell-based assay from Euroimmune and partly at the Mayo-Clinic
(Rochester) as described [1].
2.6. Statistics
Statistical analyses were performed using SAS software (V 9.1).
Because of non-normal distribution the median and interquartile
range (IQR) were presented. Independent variables were compared
using the Kruskal–Wallis test and general linear models (GLM). Gen-
eral linear models (GLM) were also used to control for ﬁxed effects.
Categorical variables were compared using the Chi-square test. The
linear relationship between continuous variables was evaluated
using the non-parametric Spearman correlation coefﬁcient. Cutoff
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The area under the curve (AUC), sensitivity and speciﬁcity levels
were presented for serum GFAP and serum S100B. Multiple correla-
tions were corrected using the Bonferroni method. Two-tailed tests
were used throughout and p values of b0.05 were accepted as
signiﬁcant.3. Results
In this multicentre setting there was a recruitment bias of patients
per disease group reﬂecting on the local expertise (Table 1). Most
patients with neuro-ophthalmological conditions came from London.
Most control patients and RRMS patients came from Nijmegen. For
the study group, NMO 27/77 (35%) came from London, 27% from
Lyon, 5% from Nijmegen and 32% from Pecs. Importantly, there was
no geographic or pre-analytical bias introduced and serum GFAP
levels between NMO patients from different towns were comparable
(p=0.15). Overall, there was a signiﬁcant age difference between the
groups with RION and MSON patients representing the youngest
cohort (F7,315=5.11, pb0.0001, Table 1).Fig. 1. Serum GFAP levels are signiﬁcantly higher in patients with NMO if compared to
other optic neuropathies (MSON, ION, CRION, UCON). For summary of the diagnostic
criteria refer to Patients and methods section.3.1. Phenotype relationship
The serumGFAP levels were signiﬁcantly different between groups
(F7,315=5.11, pb0.001, Fig. 1). The difference in serum GFAP levels
did not depend on age (p=0.99) and serum GFAP levels did not
correlate with age (R=−0.006, p=0.9).
The median serum GFAP levels were signiﬁcantly higher in pa-
tients with NMO (4.83 pg/mL) if compared to MSON (1.5 pg/mL,
p=0.0001), UCON (1.92 pg/mL, pb0.01), ION (0.0 pg/mL, pb0.05),
RION (1.3 pg/mL, pb0.0001) and CRION (2.2 pg/mL, p=0.01). The
ROC analysis for serumGFAP levels as a diagnostic test for NMO revealed
an AUC of 0.754 with an optimised cutoff level of 3.01 pg/mL GFAP.
Based on this cutoff level the diagnostic sensitivity of serum GFAP for
NMO was 23% with a speciﬁcity of 33%.
The serum S100B levels did not differ statistically between groups
(p=0.55). Therefore no further ROC analyses were performed. Serum
S100B levels did not correlate with age (R=0.055, p=0.43).
Likewise, a post-hoc analyses on a pooled group of patients with
ION and RION who were AQP4 seropositive with those who were
not did not reveal any statistical signiﬁcant difference for either
serum GFAP or S100B levels (data not shown).Table 1
Patient demographics. UK = United Kingdom, F = France, NL = The Netherlands, HR =
Hungary, CTRL = controls, MSON = multiple sclerosis optic neuritis, ION = isolated
optic neuritis, RION= relapsing isolated optic neuritis, CRION= chronic relapsing isolated
optic neuropathies, UCON=atypical optic neuritis, NMO=neuromyelitis optica, RRMS=
relapsing remitting multiple sclerosis. The median (range), the number (%) is shown,
AQP4-ab = anti-AQP4 auto-antibodies, n.d. = not determined, the proportion of AQP4-ab
positive samples of the total number of samples tested (%) is shown.
Disease Age
(years)
Gender AQP4-ab Number per country Total
number
F:M UK F NL HR
CTRL 40 (18–50) 22:23 n.d. 0 0 45 0 45
MSON 35 (17–54) 26:12 0/29 (0%) 35 3 0 0 38
ION 38 (21–68) 8:3 0/8 (0%) 11 0 0 0 11
RION 37 (16–69) 36:12 4/38 (11%) 29 0 0 19 48
CRION 41 (29–69) 14:4 0/15 (0%) 18 0 0 0 18
UCON 39 (15–68) 27:10a 2/18 (11%) 39 0 0 0 39
NMO 41 (14–66) 58:19 36/63 (57%) 27 21 4 25 77
RRMS 41 (21–66) 34:13 0/1 (0%) 1 0 46 0 47
Total 39 (14–69) 225:96b 42/172 (24%) 160 24 95 44 323
a The gender was not recorded in two patients.
b The gender was not documented in two patients with UCON.3.2. NMO subgroups
Patients with NMO were dichotomised according to their clinical
presentation into those with an acute myelitis (n=55) and those
without (n=22). There was no statistical signiﬁcant difference
between the two groups (p=0.39).
3.3. Timing of sample acquisition
Because CSF GFAP and S100B levels were reported to be higher
during a relapse compared to remission [9,10,12] we tested whether
this is also the case for serum concentrations. The median serum
GFAP levels during a relapse were 4.6 pg/mL (IQR 2.4–7.4 pg/mL) in
NMO compared to 2.6 ng/mL (0–5.2 pg/mL, p=0.33) in remission.
Reliable data on the timing of the relapse was not available in 25
patients. The median serum S100B levels during a relapse wereFig. 2. The relationship between serum GFAP levels and AQP4 serostatus (closed cir-
cles=seropositive, open circles=seronegative) in patients with RION and NMO.
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(0.6–2.1 ng/mL, p=0.70) in remission.
For patients with RRMS serum GFAP levels during a relapse were
5.0 pg/mL (0–7.3 pg/mL) compared to 3.2 pg/mL (0.8–5.0 pg/mL,
p=0.57) in remission. The serum S100B levels were 1.7 ng/mL
(0.7–2.8 ng/mL) compared to 2.0 ng/mL (1.0–2.0 ng/mL, p=0.47) in
remission.
There was no signiﬁcant correlation of either serum GFAP or
serum S100B levels with the delay between onset of relapse and
time of sampling in any of the disease groups (data not shown).
Disease activity as assessed by the number of relapses correlated
with serum S100B levels in MSON patients (Fig. 3).
3.4. Biomarker relationships
In patients with RION tested positive for antibodies against
AQP4 serum GFAP levels were signiﬁcantly higher, 7.9 pg/mL
(6.4–10.5 pg/mL) compared to AQP4 seronegative patients, 1.3 pg/mL
(0–2.3 pg/mL, p=0.0028, Fig. 2). There was no statistical difference
for serum GFAP or S100B levels in NMO based on the AQP4 serostatus.
There was no signiﬁcant correlation between the concentration of
serum GFAP and serum S100B in any of the disease groups.
4. Discussion
The main ﬁnding of this study is higher median serum GFAP levels
in patients with NMO (4.83 pg/mL) compared to patients with other
forms of optic neuropathy (1.5–2.2 pg/mL). These data support the
hypothesis that complement mediated autoimmunity against AQP4
leads to astrocytic damage and causes release of GFAP [6,7,11]. In con-
trast to the concentration of GFAP in the CSF the serum concentration
is only of minor diagnostic value for NMO. The data on serum GFAP
levels from speciﬁc cohorts of optic neuropathies [13] is further offset
by the large overlap with the serum GFAP concentration in neurolog-
ical controls in which no overt pathology was found (Fig. 1). The
minor diagnostic value of serum GFAP levels is further underlined
by the low speciﬁcity limit of 33%. In this study serum S100B levels
were not of diagnostic value for NMO.
In this cross-sectional study serum GFAP and S100B levels were
not statistically inﬂuenced by the timing of serum sampling withFig. 3. In patients with MSON, serum S100B levels correlated with disease activity as
assessed by the number of relapses (R=0.83, p=0.005).either relation to relapse/remission or time delay from an acute re-
lapse. There was, however a trend for almost two-fold higher median
serum GFAP levels during a relapse (4.6 pg/mL) compared to remis-
sion (2.6 pg/mL) and the study may have been underpowered to re-
veal this difference on a statistical level. Notably, data on presence
of a relapse was ambiguous in 25 patients. On the other hand and in
view of previously published work [26–29], the data may suggest, at
least on a group level, that the concentrations of GFAP and S100B in
the serum are poorly correlated to the concentrations found in the
CSF compartment. For S100B, there are a number of studies demon-
strating that serum and CSF levels were not correlated in a number
of diseases including MS [26–29]. Likewise, a recent study on serum
GFAP and S100B levels in NMO did not ﬁnd a correlation of concen-
trations between body ﬂuid compartments [30]. In contrast to these
results one study did ﬁnd in AQP4 autoantibody positive patients
that serum and CSF levels of both glial biomarkers were highly corre-
lated [31]. In this respect a shortcoming of our study is that we only
had access to serum samples for analysis.
Another limitation of our study is a patient referral bias due to the
multicentre setting with different clinical focuses. Almost all patients
with optic neuropathies other than NMO were recruited in London.
This may be relevant because of the classiﬁcation in ION, RION and
UCON based on clinical and MRI data. Inspection of Table 1 shows
an 11% AQP4 seropositive rate for patients with UCON and RION.
This is very similar to the 10% AQP4 seropositive rate found for the
overlap with systemic rheumatoid diseases [20,21]. Two large studies
on AQP4 antibodies in patients with different forms of optic neurop-
athies found about 5–6% to be seropositive [13,32] which is less
than the 25% reported in the original paper describing the antibody
[1]. We would be hesitant to draw any conclusions on the diagnostic
value of serum GFAP levels in this context, but long-term follow up
studies of these patients including a more extensive and standardised
auto-antibody panel titres may be informative. Such studies are war-
ranted because if a link to systemic rheumatoid autoimmunity can be
demonstrated, rigorous immunosuppression may be required for
protection of visual function.
A further limitation of our study was that we were not able to
compare the sensitivity and speciﬁcity levels of serum GFAP and/or
S100B levels to the AQP4 serostatus for two reasons. First, different
assays for presence of AQP4 auto-antibodies were used in this multi-
centre study [1,8,24,25]. There are likely signiﬁcant differences of the
analytical sensitivity between these assays as assessed by a blinded
multicentre study. On the other side this situation is not uncommon
in a multi-centre setting and has been discussed extensively [21].
Second, for this study samples were analysed in all NMO patients,
but not systematically in all patients of the other groups. In this con-
text it should be mentioned that at the start of this prospective study
the AQP4 auto-antibody had not yet been discovered.
A major shortcoming of our study is that the aetiopathogenesis of
MSON, ION, RION and CRION remains unknown. There is no biological
evidence showing that the aetiology of MSON is different from the
aetiology of RION. The same applies to the difference between
CRION and neurosarcoidosis as already discussed [19]. Another short-
coming was that we did not have systematic longitudinal clinical data
to assess the potential prognostic value of serum GFAP levels in this
cohort. These major limitations aside, the present data supports the
concept of more substantial glial pathology in NMO compared to MS
or other optic neuropathies. Importantly, this was the case indepen-
dent to whether or not patients with NMO presented with an acute
myelitis. For NMO, at least, there is good experimental evidence for
complement mediated autoimmune damage to the astrocytes. It is
therefore plausible to assume that the observed increase of serum
GFAP levels is related to the underlying pathology.
It is not surprising to note that serum S100B levels were not of
diagnostic value because an elevation of the concentration of S100B
is also reported in a range of other acute neurological diseases
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likely to introduce measurement noise. The data on higher serum
S100B levels in patients with more active MS is consistent with previ-
ous studies suggesting serum S100B to be a biomarker for micro- and
macroglial activity [29,36]. Because the more disseminated pathology
in the MS brain compared to local pathology in optic neuropathies,
serum S100B levels may be investigated as a potential biomarker for
controlling inﬂammatory disease activity in RR or SP MS, but not
PPMS [37].
5. Conclusion
This study demonstrates that unlike the considerable higher CSF
GFAP and S100B levels in acute NMO compared to other neurological
diseases [9–12], serum GFAP levels are of limited value in a highly
selected cohort of patients with optic neuropathies and serum S100B
levels are of no diagnostic value.
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